SYNAPT G2-S High Definition MS (HDMS) System

Similar documents
Data Independent MALDI Imaging HDMS E for Visualization and Identification of Lipids Directly from a Single Tissue Section

[application note] DIRECT TISSUE IMAGING AND CHARACTERIZATION OF PHOSPHOLIPIDS USING A MALDI SYNAPT HDMS SYSTEM

Applying a Novel Glycan Tagging Reagent, RapiFluor-MS, and an Integrated UPLC-FLR/QTof MS System for Low Abundant N-Glycan Analysis

Profiling Flavonoid Isomers in Highly Complex Citrus Juice Samples Using UPLC Ion Mobility Time-of-Flight Mass Spectrometry

INTRODUCTION TO MALDI IMAGING

[ APPLICATION NOTE ] APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS

ACHIEVEMENTS ARE LIMITED ONLY BY ASPIRATIONS.

PosterREPRINT RAPID, SELECTIVE SCREENING OF URINE SAMPLES FOR GLUCURONIDES BY LC/MS/MS INTRODUCTION ABSTRACT

Impurity Identification using a Quadrupole - Time of Flight Mass Spectrometer QTOF

O O H. Robert S. Plumb and Paul D. Rainville Waters Corporation, Milford, MA, U.S. INTRODUCTION EXPERIMENTAL. LC /MS conditions

Rapid, Simple Impurity Characterization with the Xevo TQ Mass Spectrometer

2. Ionization Sources 3. Mass Analyzers 4. Tandem Mass Spectrometry

Chemical Analysis Business Operations Waters Corporation Milford MA

INTRODUCTION CH 3 CH CH 3 3. C 37 H 48 N 6 O 5 S 2, molecular weight Figure 1. The Xevo QTof MS System.

Automated Lipid Identification Using UPLC/HDMS E in Combination with SimLipid

Increased Identification Coverage and Throughput for Complex Lipidomes

John Haselden 1, Gordon Dear 1, Jennifer H. Granger 2, and Robert S. Plumb 2. 1GlaxoSmithKline, Ware, UK; 2 Waters Corporation, Milford, MA, USA

Rapid Lipid Profiling of Serum by Reverse Phase UPLC-Tandem Quadrupole MS

[ APPLICATION NOTE ] High Sensitivity Intact Monoclonal Antibody (mab) HRMS Quantification APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS

A NOVEL METHOD OF M/Z DRIFT CORRECTION FOR OA-TOF MASS SPECTROMETERS BASED ON CONSTRUCTION OF LIBRARIES OF MATRIX COMPONENTS.

LC/MS/MS SOLUTIONS FOR LIPIDOMICS. Biomarker and Omics Solutions FOR DISCOVERY AND TARGETED LIPIDOMICS

Jose Castro-Perez, Henry Shion, Kate Yu, John Shockcor, Emma Marsden-Edwards, Jeff Goshawk Waters Corporation, Milford, MA, U.S. and Manchester, UK

PTM Discovery Method for Automated Identification and Sequencing of Phosphopeptides Using the Q TRAP LC/MS/MS System

A Definitive Lipidomics Workflow for Human Plasma Utilizing Off-line Enrichment and Class Specific Separation of Phospholipids

Latest Innovations in LC/MS/MS from Waters for Metabolism and Bioanalytical Applications

ApplicationNOTE EXACT MASS MEASUREMENT OF ACTIVE COMPONENTS OF TRADITIONAL HERBAL MEDICINES BY ORTHOGONAL ACCELERATION TIME-OF-FLIGHT.

A UPLC/MS Approach for the Diagnosis of Inborn Errors of Metabolism

Increasing the Peak Capacity of LC/MS/MS Systems for the Analysis of Complex Biological Samples

Advantages of Ion Mobility Q-TOF for Characterization of Diverse Biological Molecules

Matrix Factor Determination with the Waters Regulated Bioanalysis System Solution

Moving from targeted towards non-targeted approaches

Improving Selectivity in Quantitative Analysis Using MS 3 on a Hybrid Quadrupole-Linear Ion Trap Mass Spectrometer

Ultra Performance Liquid Chromatography Coupled to Orthogonal Quadrupole TOF MS(MS) for Metabolite Identification

Analysis of Testosterone, Androstenedione, and Dehydroepiandrosterone Sulfate in Serum for Clinical Research

More structural information with MS n

Don t miss a thing on your peptide mapping journey How to get full coverage peptide maps using high resolution accurate mass spectrometry

Lecture 3. Tandem MS & Protein Sequencing

Analysis of N-Linked Glycans from Coagulation Factor IX, Recombinant and Plasma Derived, Using HILIC UPLC/FLR/QTof MS

New Developments in LC-IMS-MS Proteomic Measurements and Informatic Analyses

NIH Public Access Author Manuscript J Proteome Res. Author manuscript; available in PMC 2014 July 05.

Quadrupole and Ion Trap Mass Analysers and an introduction to Resolution

UPLC-MS/MS Analysis of Azole Antifungals in Serum for Clinical Research

UPLC/MS Monitoring of Water-Soluble Vitamin Bs in Cell Culture Media in Minutes

Characterization of an Unknown Compound Using the LTQ Orbitrap

Targeted and untargeted metabolic profiling by incorporating scanning FAIMS into LC-MS. Kayleigh Arthur

New Instruments and Services

Considerations of the use of Triple Quadrupoles or Ion Traps in Quantitative Applications

Advancing your Forensic Toxicology Analyses; Adopting the Latest in Mass Spectrometry Innovations

Characterization of Protein Impurities by Peptide Mapping with UPLC/MS E

2013 Waters Corporation 1

Mass Spectrometry. Actual Instrumentation

Biotherapeutics. Biopharmaceutical Sciences Group Waters Corporation Waters Corporation 1

MALDI Imaging Drug Imaging Detlev Suckau Head of R&D MALDI Bruker Daltonik GmbH. December 19,

Agilent 6410 Triple Quadrupole LC/MS. Sensitivity, Reliability, Value

CHARACTERIZATION AND DETECTION OF OLIVE OIL ADULTERATIONS USING CHEMOMETRICS

Comparison of mass spectrometers performances

SWATH Acquisition Enables the Ultra-Fast and Accurate Determination of Novel Synthetic Opioids

A RAPID AND SENSITIVE UPLC/UV/MS METHOD FOR SIMVASTATIN AND LOVA S TAT IN IN SU P P O RT O F C L E A NING VA L I DAT IO N S T U DIES

AB Sciex QStar XL. AIMS Instrumentation & Sample Report Documentation. chemistry

ION MOBILITY COUPLED TO HIGH RESOLUTION MASS SPECTROMETRY: THE POSSIBILITIES, THE LIMITATIONS

Quantification of Budesonide Using UPLC and Xevo TQ-S

Meeting Challenging Requirements for the Quantitation of Regulated Growth Promoters Dexamethasone and Betamethasone in Liver and Milk

Rapid Analysis of Water-Soluble Vitamins in Infant Formula by Standard-Addition

Mass Spectrometry at the Laboratory of Food Chemistry. Edwin Bakx Laboratory of Food Chemistry Wageningen University

Quantitation by High Resolution Mass Spectrometry: Case Study of TOF MS for the Quantitation of Allopurinol from Human Plasma

Small Molecule Science: Experimental designs for achieving ultra trace analysis

Discovery Metabolomics - Quantitative Profiling of the Metabolome using TripleTOF Technology

Comprehensive Forensic Toxicology Screening in Serum using On-Line SPE LC-MS/MS

1. Sample Introduction to MS Systems:

Quantitative Analysis of Drugs of Abuse in Urine using UHPLC Coupled to Accurate Mass AxION 2 TOF Mass Spectrometer

How to Use TOF and Q-TOF Mass Spectrometers

Technical Note # TN-31 Redefining MALDI-TOF/TOF Performance

Advances in Hybrid Mass Spectrometry

for new contaminants at ultra trace level by using high resolution mass spectrometry

Amadeo R. Fernández-Alba

MS/MS Scan Modes. Eötvös University, Budapest April 16, MS/MS Scan Modes. Árpád Somogyi. Product Ion Scan Select. Scan. Precursor Ion Scan Scan

[ Care and Use Manual ]

MS/MS Library Creation of Q-TOF LC/MS Data for MassHunter PCDL Manager

Bioanalytical Quantitation of Biotherapeutics Using Intact Protein vs. Proteolytic Peptides by LC-HR/AM on a Q Exactive MS

SUPPORTING INFORMATION. Lysine Carbonylation is a Previously Unrecognized Contributor. to Peroxidase Activation of Cytochrome c by Chloramine-T

SelexION Technology for Lipid Analysis: Pushing the Boundaries of Lipidomics

Join the mass movement towards mass spectrometry

Identification & Confirmation of Structurally Related Degradation Products of Simvastatin

Metabolite identification in metabolomics: Database and interpretation of MSMS spectra

PosterREPRINT A NOVEL APPROACH TO MALDI-TOF-MS SAMPLE PREPARATION. Presented at ABRF 2002, Austin, Texas, USA, 9th - 12th March 2002.

PosterREPRINT AN AUTOMATED METHOD TO SELF-CALIBRATE AND REJECT NOISE FROM MALDI PEPTIDE MASS FINGERPRINT SPECTRA

Analysis of the Non-Ionic Surfactant Triton-X Using UltraPerformance Convergence Chromatography (UPC 2 ) with MS and UV Detection

SEPARATION OF BRANCHED PFOS ISOMERS BY UPLC WITH MS/MS DETECTION

Identification of Ginsenosides Using the SCIEX X500R QTOF System

LC/QTOF Discovery of Previously Unreported Microcystins in Alberta Lake Waters

PosterREPRINT INTRODUCTION. 2-D PAGE of Mouse Liver Samples. 2-D PAGE of E.coli Samples. Digestion / Cleanup. EXPERIMENTAL 1-D PAGE of BSA Samples

PosterREPRINT EVALUATION OF A RF-ONLY STACKED RING BASED COLLISION CELL WITH AXIAL FIELD FOR THE LC-MS-MS ANALYSIS OF THE METABOLITES OF RABEPRAZOLE

Use of a Tandem Mass Spectrometry Research Method for the Analysis of Amino Acids and Acylcarnitines in Dried Blood Spots

Ultra High Definition Optimizing all Analytical Dimensions

New Mass Spectrometry Tools to Transform Metabolomics and Lipidomics

QSTAR Operation. May 3, Bob Seward

Using Software Tools to Improve the Detection of Impurities by LC/MS. Application Note. Christine Miller Agilent Technologies.

Application Note # LCMS-89 High quantification efficiency in plasma targeted proteomics with a full-capability discovery Q-TOF platform

Metabolite identification in metabolomics: Metlin Database and interpretation of MSMS spectra

APPLICATION OF ELEVATED RESOLUTION GC-TOF-MS FOR THE MULTIRESIDUE ANALYSIS OF PESTICIDES IN FOOD

Transcription:

SYNAPT G2-S High Definition MS (HDMS) System High performance, versatility, and workflow efficiency of your MS system all play a crucial role in your ability to successfully reach your scientific and business goals and that s what drives the evolution of Waters SYNAPT technology. SYNAPT G2-S combines revolutionary StepWave ion optics with proven Quantitative Tof (QuanTof ) and High Definition MS technologies to provide the highest levels of sensitivity, selectivity, and speed. With Waters leading MS Informatics, SYNAPT G2-S will help you efficiently extract the maximum information from your most challenging samples in less time so you can be first to discover, first to publish, first to succeed. SYNAPT G2-S HDMS is a high resolution exact mass MS/MS platform designed to get you to the right result, faster no matter how challenging your application is. When you want to reach beyond the boundaries of conventional mass spectrometry, SYNAPT G2-S High Definition Mass Spectrometry (HDMS ) provides a new dimension to your discovery capability by combining high efficiency ion mobility based measurements and separations with high performance tandem mass spectrometry. By enabling you to differentiate samples by size, shape, and charge as well as mass this unique capability allows you to make discoveries that simply aren t possible any other way. PERFORMANCE SPECIFICATIONS The SYNAPT G2-S HDMS System can operate in two modes: (a) TOF mode (b) Mobility-TOF mode TOF Mass Resolution in Positive Ion 10,000 FWHM measured on the (M + 6H) 6+ isotope cluster from bovine insulin (m/z 956) 20,000 FWHM measured on the (M + 6H) 6+ isotope cluster from bovine insulin (m/z 956) (c) High Resolution Mode 40,000 FWHM measured on the (M + 6H) 6+ isotope cluster from bovine insulin (m/z 956) 1

TOF Mass Resolution in Negative Ion 10,000 FWHM measured on the (M - 4H) 4- isotope cluster from bovine insulin (m/z 1431) 20,000 FWHM measured on the (M - 4H) 4- isotope cluster from bovine insulin (m/z 1431) (c) High Resolution Mode 40,000 FWHM measured on the (M - 4H) 4- isotope cluster from bovine insulin (m/z 1431) Positive Ion MS Sensitivity a) Sensitivity Mode The peak at m/z 556 from a solution of 50 pg/μl leucine enkephalin in 50/50 acetonitrile/water 41,600 ions per second. The instrument will be tuned to 10,000 resolution (as demonstrated on bovine insulin) and the mass range will be set to a maximum of 1200 m/z. The peak at m/z 556 from a solution of 50 pg/μl leucine enkephalin in 50/50 acetonitrile/water 20,800 ions per second. The instrument will be tuned to 20,000 resolution (as demonstrated on bovine insulin) and the mass range will be set to a maximum of 1200 m/z. (c) Enhanced Duty Cycle (EDC) Mode The peak at m/z 556 from a solution of 10 pg/μl leucine enkephalin in 50/50 acetonitrile/water 24,800 ions per second. The instrument will be tuned to 20,000 resolution (as demonstrated on bovine insulin), with sensitivity set to a maximum at 556 m/z. Negative Ion MS Sensitivity The peak at m/z 503 from a solution of 500 pg/μl raffinose in 70/30 acetonitrile/water (no additives), infused at a flow rate of 5 μl/min, will have an intensity of greater than 44,800 ions per second. The instrument will be tuned to 10,000 resolution (as demonstrated on bovine insulin), and the mass range will be set to a maximum of 1200 m/z. The peak at m/z 503 from a solution of 500 pg/μl raffinose in 70/30 acetonitrile/water (no additives), infused at a flow rate of 5 μl/min, will have an intensity of greater than 22,400 ions per second. The instrument will be tuned to 20,000 resolution (as demonstrated on bovine insulin), and the mass range will be set to a maximum of 1200 m/z. Positive Ion MS/MS Sensitivity Using a [Glu 1 ] -Fibrinopeptide B solution of 100 fmol/μl, at a flow rate of 5 μl/min and with the instrument tuned for 10,000 resolution (as demonstrated on bovine insulin), the intensity of the most intense y sequence ion from the MS/MS spectrum of the doubly charged precursor ion (785.8 m/z) will be greater than 3,200 ions per second. The instrument mass range will be set to a maximum of 2000 m/z. 2

Using a [Glu 1 ] -Fibrinopeptide B solution of 100 fmol/μl, at a flow rate of 5μL/min and with the instrument tuned for 20,000 resolution (as demonstrated on bovine insulin), the intensity of the most intense y sequence ion from the MS/MS spectrum of the doubly charged precursor ion (785.8 m/z) will be greater than 1,600 ions per second. The instrument mass range will be set to a maximum of 2000 m/z. Negative Ion MS/MS Sensitivity Using a solution of 500 pg/μl raffinose in 70/30 acetonitrile/water, at a flow rate of 5 μl/min and with the instrument tuned for 10,000 resolution (as demonstrated on bovine insulin), the intensity of the fragment ion at 179.1 m/z in the MS/MS spectrum of the precursor ion at 503.2 m/z will be greater than 3,200 ions per second. The instrument mass range will be set to a maximum of 1200 m/z. Using a solution of 500 pg/μl raffinose in 70/30 acetonitrile/water, at a flow rate of 5 μl/min and with the instrument tuned for 20,000 resolution (as demonstrated on bovine insulin), the intensity of the fragment ion at 179.1 m/z in the MS/MS spectrum of the precursor ion at 503.2 m/z will be greater than 1,600 ions per second. The instrument mass range will be set to 1200 m/z. Mass Scale Calibration Accuracy Mass Measurement Accuracy Mass Range Acquisition Rate Dynamic Range High Mass Precursor Selection The mass measurement accuracy of the instrument in High Resolution mode, using internal lock masses, is such that the RMS error between the measured and the accepted masses of peaks which have sufficient intensity, and are free from interference from other masses, will be less than 1 ppm over the range 150 to 900 m/z. The mass measurement accuracy of the instrument, in High Resolution mode, will be better than 1 ppm RMS, based on 10 consecutive repeat measurements of the [M + Na] + ion of raffinose (m/z 527.1588), using the [M + H] + ions of leucine enkephalin (m/z 556.2771) and 4-acetamidophenol (m/z 152.0712) as the LockSpray lockmasses. Analyte and lockmass peaks must have sufficient intensity and be free of interference from other masses. The TOF mass range is 20 to 100,000 m/z in Resolution mode, and 20 to 32,000 m/z in High Resolution mode. The m/z transmission range for a quadrupole in non-resolving mode is 20 to 16,000 m/z for a 4000 m/z quadrupole, and 20 to 32,000 m/z for an 8000 m/z quadrupole. Mass spectra can be acquired up to a rate of 30 scans per second (mode dependent). The dynamic range in High Resolution mode, defined as the range of peak intensities that will give better than 3 ppm accurate mass RMS for 10 sec of data without pdre (programmable Dynamic Range Enhancement), is at least 4 orders of magnitude, when measured on the m/z 556.2771 peak from leucine enkephalin. Applicable to instruments with 8000 m/z and 32,000 m/z quadrupoles only. The low energy MS/MS spectrum of m/z 5569.1 from a solution of 2 μg/μl sodium iodide in 50/50 isopropanol/water will contain only m/z 5569.1 and its fragments. The intensity of the largest fragment ion will be less than 5% of the intensity of the precursor ion. MS/MS data will be acquired over the mass range 100 8000 m/z, with collision energy of 10 ev. 3

MALDI PERFORMANCE SPECIFICATIONS Mass Resolution in Positive Ion Mass Resolution in Negative Ion Positive Ion MS Sensitivity (a) Resolution Mode 16,000 measured on the (M + H)+ isotope cluster from insulin B chain (m/z 3494.6) (b) High Resolution Mode 32,000 measured on the (M + H)+ isotope cluster from insulin B chain (m/z 3494.6) (a) Resolution Mode 16,000 measured on the (M - H)- isotope cluster from insulin B chain (m/z 3492.6) (b) High Resolution Mode 32,000 measured on the (M - H)- isotope cluster from insulin B chain (m/z 3492.6) The peak at m/z 1570.6774 from 10 fmol of [Glu 1 ] -Fibrinopeptide B will have an intensity of greater than 30,000 counts acquired from an entire line through a sample well. The instrument m/z range will be set to 2000. subtracted the signal-to-noise ratio will be greater than 90:1 when compared to a region of the m/z scale between 1768 and 1818. Negative Ion MS Sensitivity The peak at m/z 1568.6618 from 100 fmol of [Glu 1 ]-Fibrinopeptide B will have an intensity of greater than 30,000 counts acquired from an entire line through a sample well. The instrument m/z range will be set to 2000. subtracted the signal-to-noise ratio will be greater than 90:1 when compared to a region of the m/z scale between 1768 and 1818. Positive Ion MS/MS Sensitivity The peak at m/z 1056.4750 (y9) from 10 fmol of [Glu 1 ] -Fibrinopeptide B will have an intensity of greater than 1000 counts for an entire line through a sample well. The instrument m/z range will be set to 2000 (Precursor+50) and the collision energy and instrument conditions set such that the intensity of this peak will be greater than 40% of the intensity of the precursor peak. subtracted the signal-to-noise ratio should be greater than 60:1 for the m/z 1056.4750 peak when compared to a region of the m/z scale between 1450 and 1490. Mass Measurement, Positive Ion The mass measurement accuracy will be better than 1 ppm RMS, measured from a mixture of PEG oligomers between m/z 700 2500; using an internal reference peak and an instrument calibration that covers the same mass range. 4

MOBILITY-TOF MODE PERFORMANCE SPECIFICATIONS The Triwave cell is the enabling technology of the SYNAPT G2-S HDMS System. It is comprised of three main components: (a) Trap T-Wave Ensures high-efficiency by trapping ions prior to ion mobility separation; the trap can also operate as a collision cell. (b) IMS T-Wave Provides reproducible separation of ions based on their mobility. (c) Transfer T-Wave Transfers separated ions to the oa-tof for mass analysis; the transfer T-Wave can also operate as a collision cell. Mobility Functionality Ion Mobility Resolution Control of Mobility Separation Separation of ions based on their mobility (size, shape, and charge) Time Aligned Parallel (TAP) fragmentation High Duty Cycle (HDC) for extended detection limits over a wide m/z range Drift Time measurements: Record drift times between 33 μs and 90 ms Infusion of a mixture of the inverse peptides ser-asp-gly-arg-gly and gly-arg-gly-asp-ser will yield doubly-charged molecular ions at m/z 246.1. The mobility separation of the m/z 246.1 ion species in Nitrogen will give two distinct arrival time peaks from which a mobility resolution (Ω/ΔΩ) of >36 will be demonstrated using collision cross section (Ω) values of 222.7 and 211.7 A2 for the ser-asp-gly-arg-gly and gly-arg-gly-asp-ser peptides respectively. (Values taken from: C Wu, WF Siems, J Klasmeier and HH Hill, Anal. Chem., 72 (2000) 391.) Control of Triwave height and velocity with linear ramps or user defined programs Ability to use different gases for mobility separation Automated control of mobility conditions for routine operation Comprehensive manual control of mobility and Triwave operation for research use Waters and SYNAPT are registered trademarks of Waters Corporation. The Science of What s Possible, StepWave, HDMS, High Definition MS, High Definition Mass Spectrometry, QuanTof, and Triwave are trademarks of Waters Corporation. All other trademarks are the property of their respective owners. 2011 Waters Corporation. Produced in the U.S.A. June 2011 720004005EN LB-PDF Waters Corporation 34 Maple Street Milford, MA 01757 U.S.A. T: 1 508 478 2000 F: 1 508 872 1990 www.waters.com